Glaxo Consumer Grows 7% Even As JV ‘Moving Parts’ Settle
This article was originally published in The Tan Sheet
An investor suggests divesting its consumer business and other segments to focus on its Rx and vaccines operations, but CEO Witty says the consumer JV’s early returns point to long-term success. “We see very significant opportunity to create value through the expansion of the margin in consumer,” he says.
You may also be interested in...
Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.
One group, CHP Canada, also recently published survey results showing more Canadians are turning to self-care during the COVID-19 pandemic. CHP Canada and Food and Consumer Products of Canada merged to create Food, Health & Consumer Products of Canada.
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.